Jäkel Oliver, Land Beate, Combs Stephanie Elisabeth, Schulz-Ertner Daniela, Debus Jürgen
Department of Medical Physics in Radiation Oncology, Heidelberg, Germany.
Radiother Oncol. 2007 May;83(2):133-8. doi: 10.1016/j.radonc.2007.03.010. Epub 2007 May 8.
The cost-effectiveness of Carbon ion radiotherapy (RT) for patients with skull base chordoma is analyzed.
Primary treatment costs and costs for recurrent tumors are estimated. The costs for treatment of recurrent tumors were estimated using a sample of 10 patients presenting with recurrent chordoma at the base of skull at DKFZ. Using various scenarios for the local control rate and reimbursements of Carbon ion therapy the cost-effectiveness of ion therapy for these tumors is analyzed.
If local control rate for skull base chordoma achieved with carbon ion therapy exceeds 70.3%, the overall treatment costs for carbon RT are lower than for conventional RTI. The cost-effectiveness ratio for carbon RT is 2539 Euro per 1% increase in survival, or 7692 Euro per additional life year.
Current results support the thesis that Carbon ion RT, although more expensive, is at least as cost-effective as advanced photon therapies for these patients. Ion RT, however, offers substantial benefits for the patients such as improved control rates and less severe side effects.
分析碳离子放疗（RT）治疗颅底脊索瘤患者的成本效益。
估算初始治疗成本和复发性肿瘤的治疗成本。利用德国癌症研究中心（DKFZ）的10例颅底复发性脊索瘤患者样本估算复发性肿瘤的治疗成本。通过设定不同的局部控制率和碳离子治疗报销方案，分析离子治疗这些肿瘤的成本效益。
如果碳离子治疗实现的颅底脊索瘤局部控制率超过70.3%，碳离子放疗的总体治疗成本低于传统放疗（RTI）。碳离子放疗的成本效益比为每生存增加1% 2539欧元，或每增加一个生命年7692欧元。
目前的结果支持这一论点，即碳离子放疗虽然成本更高，但对于这些患者而言，至少与先进的光子治疗具有相同的成本效益。然而，离子放疗为患者带来了显著益处，如提高控制率和减轻副作用。
